Каприн А.Д., Старинский В.В., Петрова Г.В. (ред.) Состояние онкологиче ской помощи населению России в 2019 году. М.; 2020. 239 с. Режим доступа: https://glavonco.ru/cancer_register/[%]D0[%]9F[%]D0[%]BE[%]D0[%]BC[%]D0[%]BE[%]D1[%]89[%]D1[%]8C[%]202019.pdf.https://glavonco.ru/cancer_register/[%]D0[%]9F[%]D0[%]BE[%]D0[%]BC[%]D0[%]BE[%]D1[%]89[%]D1[%]8C[%]202019.pdf
Каприн А.Д., Старинский В.В., Петрова Г.В. (ред.) Состояние онкологиче ской помощи населению России в 2019 году. М.; 2020. 239 с. Режим доступа: https://glavonco.ru/cancer_register/[%]D0[%]9F[%]D0[%]BE[%]D0[%]BC[%]D0[%]BE[%]D1[%]89[%]D1[%]8C[%]202019.pdf.https://glavonco.ru/cancer_register/[%]D0[%]9F[%]D0[%]BE[%]D0[%]BC[%]D0[%]BE[%]D1[%]89[%]D1[%]8C[%]202019.pdf
Каприн А.Д., Старинский В.В., Петрова Г.В. (ред.) Злокачественные ново образования в России в 2018 году (заболеваемость и смертность). М.; 2019. 250 p. Режим доступа: https://glavonco.ru/cancer_register/[%]D0[%]97[%]D0[%]B0[%]D0[%]B1[%]D0[%]BE[%]D0[%]BB_2018_[%]D0[%]AD[%]D0[%]BB[%]D0[%]B5[%]D 0[%]BA[%]D1[%]82[%]D1[%]80.pdf.https://glavonco.ru/cancer_register/[%]D0[%]97[%]D0[%]B0[%]D0[%]B1[%]D0[%]BE[%]D0[%]BB_2018_[%]D0[%]AD[%]D0[%]BB[%]D0[%]B5[%]D
Каприн А.Д., Старинский В.В., Петрова Г.В. (ред.) Злокачественные ново образования в России в 2018 году (заболеваемость и смертность). М.; 2019. 250 p. Режим доступа: https://glavonco.ru/cancer_register/[%]D0[%]97[%]D0[%]B0[%]D0[%]B1[%]D0[%]BE[%]D0[%]BB_2018_[%]D0[%]AD[%]D0[%]BB[%]D0[%]B5[%]D 0[%]BA[%]D1[%]82[%]D1[%]80.pdf.https://glavonco.ru/cancer_register/[%]D0[%]97[%]D0[%]B0[%]D0[%]B1[%]D0[%]BE[%]D0[%]BB_2018_[%]D0[%]AD[%]D0[%]BB[%]D0[%]B5[%]D0[%]BA[%]D1[%]82[%]D1[%]80.pdf
Gupta N., Devgan A., Bansal I., Olsavsky T.D., Li S., Abdelbaki A., Kumar Y. Usefulness of radium-223 in patients with bone metastases. Baylor University Medical Center Proceedings. 2017;30(4):424–426. doi: 10.1080/08998280.2017.11930213..
DOI: 10.1080/08998280.2017.11930213
Scher H.I., Morris M.J., Basch E., Heller G. End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. J Clin Oncol. 2011;29(27):3695–3704. doi: 10.1200/JCO.2011.35.8648..
DOI: 10.1200/JCO.2011.35.8648
Bubendorf L., Schöpfer A., Wagner U., Sauter G., Moch H., Willi N. et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol. 2000;31(5):578–583. doi: 10.1053/hp.2000.6698..
DOI: 10.1053/hp.2000.6698
Костин А.А., Мурадян А.Г., Толкачев А.О., Попов С.В. Радий-223. Место в лечении метастатического кастрационно-рефрактерного рака предстательной железы. Исследования и практика в медицине. 2017;4(4):79–88. doi: 10.17709/2409-2231-2017-4-4-9..
DOI: 10.17709/2409-2231-2017-4-4-9
Logothetis C., Morris M.J., Den R., Coleman R.E. Current perspectives on bone metastases in castrate-resistant prostate cancer. Cancer Metastasis Rev. 2018;37:189–196. doi: 10.1007/s10555-017-9719-4..
DOI: 10.1007/s10555-017-9719-4
Rizzini E.L., Dionisi V., Ghedini P., Morganti A.G., Fanti S., Monari F. Clinical aspects of mCRPC management in patients treated with radium-223. Sci Rep. 2020;10:6681. doi: 10.1038/s41598-020-63302-2..
DOI: 10.1038/s41598-020-63302-2
Soldatos T.G., Iakovou I., Sachpekidis C. Retrospective Toxicological Profiling of Radium-223 Dichloride for the Treatment of Bone Metastases in Prostate Cancer Using Adverse Event Data. Medicina. 2019;55(5):149. doi: 10.3390/medicina55050149..
DOI: 10.3390/medicina55050149
Taylor C.D., Elson P., Trump D.L. Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol. 1993;11(11):2167–2172. doi: 10.1200/JCO.1993.11.11.2167..
DOI: 10.1200/JCO.1993.11.11.2167
Tannock I.F., de Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–1512. doi: 10.1056/NEJMoa040720..
DOI: 10.1056/NEJMoa040720
de Bono J.S., Oudard S., Ozguroglu M., Hansen S., Machiels J.P., Kocak I. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castrationresistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147–1154. doi: 10.1016/S0140-6736(10)61389-X..
DOI: 10.1016/S0140-6736(10)61389-X
Beer T.M., Armstrong A.J., Rathkopf D.E., Loriot Y., Sternberg C.N., Higano C.S. et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424–433. doi: 10.1056/NEJMoa1405095..
DOI: 10.1056/NEJMoa1405095
de Bono J.S., Logothetis C.J., Molina A., Fizazi K., North S., Chu L. et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995–2005. doi: 10.1056/NEJMoa1014618..
DOI: 10.1056/NEJMoa1014618
Ryan C.J., Smith M.R., de Bono J.S., Molina A., Logothetis C.J., de Souza P. et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138–148. doi: 10.1056/NEJMoa1209096..
DOI: 10.1056/NEJMoa1209096
Scher H.I., Fizazi K., Saad F., Taplin M.E., Sternberg C.N., Miller K. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–1197. doi: 10.1056/NEJMoa1207506..
DOI: 10.1056/NEJMoa1207506
Parker C., Nilsson S., Heinrich D., Helle S.I., O’Sullivan J.M., Fossa S.D. et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213–223. doi: 10.1056/nejmoa1213755..
DOI: 10.1056/nejmoa1213755
Antonarakis E.S., Lu C., Luber B., Wang H., Chen Y., Nakazawa M. et al. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncol. 2015;1(5):582–591. doi: 10.1001/jamaoncol.2015.1341..
DOI: 10.1001/jamaoncol.2015.1341
Antonarakis E.S., Lu C., Wang H., Luber B., Nakazawa M., Roeser J.C. et al. AR-V7 and resistance to enzalutamide andabiraterone in prostate cancer. N Engl J Med. 2014;371(11):1028–1038. doi: 10.1056/NEJMoa1315815..
DOI: 10.1056/NEJMoa1315815
Thadani-Mulero M., Portella L., Sun S., Sung M., Matov A., Vessella R.L. et al. Androgen receptor splicevariants determine taxane sensitivity in prostate cancer. Cancer Res. 2014;74(8):2270–2282. doi: 10.1158/0008-5472.CAN-13-2876..
DOI: 10.1158/0008-5472.CAN-13-2876
Thadani-Mulero M., Portella L., Sun S., Sung M., Matov A., Vessella R.L. et al. Androgen receptor splicevariants determine taxane sensitivity in prostate cancer. Cancer Res. 2014;74(8):2270–2282. doi: 10.1158/0008-5472.CAN-13-2876..
DOI: 10.1158/0008-5472.CAN- 13-2876
Caffo O., Lunardi A., Trentin C., Maines F., Veccia A., Galligioni E. Optimal sequencing of new drugs in metastatic castration-resistant prostate cancer: Dream or reality? Curr Drug Targets. 2016;17(11):1301–1308. doi: 10.2174/1389450117666160101121317..
DOI: 10.2174/1389450117666160101121317
Caffo O., Lunardi A., Trentin C., Maines F., Veccia A., Galligioni E. Optimal sequencing of new drugs in metastatic castration-resistant prostate cancer: Dream or reality? Curr Drug Targets. 2016;17(11):1301–1308. doi: 10.2174/1389450117666160101121317..
DOI: 10.2 174/1389450117666160101121317
Грицкевич А.А., Мишугин С.В., Русаков И.Г. Возможности применения радия-223 в лечении рака предстательной железы. Медицинский совет. 2017;(6):118–122. doi: 10.21518/2079-701X-2017-6-118-122..
DOI: 10.21518/2079-701X-2017-6-118-122
Грицкевич А.А., Мишугин С.В., Русаков И.Г. Возможности применения радия-223 в лечении рака предстательной железы. Медицинский совет. 2017;(6):118–122. doi: 10.21518/2079-701X-2017-6-118-122..
DOI: 10.21518/2079-701X- 2017-6-118-122
Bruland O.S., Nilsson S., Fisher D.R., Larsen R.H. High-Linear Energy Transfer Irradiation Targeted to Skeletal Metastases by the α-Emitter 223Ra: Adjuvant or Alternative to Conventional Modalities? Clin Cancer Res. 2006;12(20):6250s-6257s. doi: 10.1158/1078-0432.CCR-06-0841..
DOI: 10.1158/1078-0432.CCR-06-0841
Carrasquillo J.A., O’Donoghue J.A., Pandit-Taskar N., Humm J.L., Rathkopf D.E., Slovin S.F. et al. Phase I pharmacokinetic and biodistribution study with escalating doses of 223 Ra-dichloride in men with castration-resistant metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2013;40(9):1384– 1393. doi: 10.1007/s00259-013-2427-6..
DOI: 10.1007/s00259-013-2427-6
Suominen M.I., Rissanen J.P., Kakonen R., Fagerlund K.M., Alhoniemi E., Mumberg D. et al. Survival benefit with radium-223 dichloride in a mouse model of breast cancer bone metastasis. J Nat Cancer Inst. 2013;105(12):908–916. doi: 10.1093/jnci/djt116..
DOI: 10.1093/jnci/djt116
Frantellizzi V., Monari F., Mascia M., Costa R., Rubini G., Spanu A. et al. Validation of the 3-variable prognostic score (3-PS) in mCRPC patients treated with 223Radium-dichloride: a national multicenter study. Ann Nucl Med. 2020;34(10):772–780. doi: 10.1007/s12149-020-01501-7..
DOI: 10.1007/s12149-020-01501-7
Nilsson S., Larsen R.H., Fosså S.D., Balteskard L., Borch K.W., Westlin J.E. et al. First Clinical Experience with α-Emitting Radium-223 in the Treatment of Skeletal Metastases. Clin Cancer Res. 2005;11(12):4451–4459. doi: 10.1158/1078-0432.CCR-04-2244..
DOI: 10.1158/1078-0432.CCR-04-2244
Nilsson S., Franzén L., Parker C., Tyrrell C., Blom R., Tennvall J. et al. Bonetargeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol. 2007;8(7):587–594. doi: 10.1016/S1470-2045(07)70147-X..
DOI: 10.1016/S1470-2045(07)70147-X
Nilsson S., Strang P., Aksnes A.K., Franzèn L., Olivier P., Pecking A. et al. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer. 2012;48(5):678–86. doi: 10.1016/j.ejca.2011.12.023..
DOI: 10.1016/j.ejca.2011.12.023
Sartor O., Coleman R., Nilsson S., Heinrich D., Helle S.I., O’Sullivan J.M. et al. Effect of radium-223 dichlorideon symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomized trial. Lancet Oncol. 2014;15(7):738–746. doi: 10.1016/S1470-2045(14)70183-4..
DOI: 10.1016/S1470-2045(14)70183-4
Hoskin P., Sartor O., O’Sullivan J.M., Johannessen D.C., Helle S.I., Logue J. et al. Efficacy and safety of radium-223 dichloride in patients with castrationresistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol. 2014;15(12):1397–1406. doi: 10.1016/S1470-2045(14)70474-7..
DOI: 10.1016/S1470-2045(14)70474-7
Nilsson S., Cislo P., Sartor O., Vogelzang N.J., Coleman R.E., O’Sullivan J.M. et al. Patient-reported quality-of-life analysis of radium-223 dichloride evaluating pain relief from the phase 3 ALSYMPCA study. Ann Oncol. 2016;27(5):868–847. doi: 10.1093/annonc/mdw065..
DOI: 10.1093/annonc/mdw065
Cislo P., Sartor A.O., Reuning-Scherer J., Shan M., Parker C. 673 Effects of radium-223 dichloride on health-related quality of life assessed by the EQ-5D utility scores in ALSYMPCA. Eur Urol Suppl. 2015;14(2):e673–e773. doi: 10.1016/S1569-9056(15)60666-2..
DOI: 10.1016/S1569-9056(15)60666-2
Nilsson S., Cislo P., Sartor O., Vogelzang N.J., Coleman R.E., O’Sullivan J.M. et al. Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study. Ann Oncol. 2016;27(5):868–874. doi: 10.1093/annonc/mdw065..
DOI: 10.1093/annonc/mdw065
Saad F., Carles J., Gillessen S., Heidenreich A., Heinrich D., Gratt J. et al. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, openlabel, single-arm phase 3b trial. Lancet Oncol. 2016;17(9):1306–1316. doi: 10.1016/S1470-2045(16)30173-5..
DOI: 10.1016/S1470-2045(16)30173-5
Sartor A.O., Fernandez D.C., Morris M.J., Iagaru A., Brown A., Almeida F. et al. Ra-223 experience in pretreated patients: EAP setting. J Clin Oncol. 2015;33(15S):5063. doi: 10.1200/JCO.2015.33.15_SUPPL.5063..
DOI: 10.1200/JCO.2015.33.15_SUPPL.5063
Vogelzang N., Fernandez D.C., Morris M.J., Iagaru A., Brown A., Almeida F. et al. Radium-223 dichloride (Ra-223) in U.S. expanded access program (EAP). J Clin Oncol. 2015;33(7S):247. doi: 10.1200/jco.2015.33.7_suppl.247..
DOI: 10.1200/jco.2015.33.7_suppl.247
Saad F., Keizman D., O’Sullivan J.M., Carles J., Wirth M., Gillessen S. et al. Analysis of overall survival by number of radium-223 injections received in an international expanded access program (iEAP). J Clin Oncol. 2016;34(15S):5082. doi: 10.1200/JCO.2016.34.15_suppl.5082..
DOI: 10.1200/JCO.2016.34.15_suppl.5082
Badrising S.K., Louhanepessy R.D., van der Noort V., Coenen J.L.L.M., Hamberg P., Beeker A. et al. A prospective observational registry evaluating clinical outcomes of Radium-223 treatment in a nonstudy population. Int J Cancer. 2020;147(4):1143–1151. doi: 10.1002/ijc.32851..
DOI: 10.1002/ijc.32851
Vogelzang N.J., Coleman R.E., Michalski J.M., Nilsson S., O’Sullivan J.M., Parker C. et al. Hematologic safety of radium-223 dichloride: baseline prognostic factors associated with myelosuppression in the ALSYMPCA trial. Clin Genitourin Cancer. 2017;15:42–52. doi: 10.1016/j.clgc.2016.07.027..
DOI: 10.1016/j.clgc.2016.07.027
Parker C.C., Coleman R.E., Sartor O., Vogelzang N.J., Bottomley D., Heinrich D. et al. Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial. Eur Urol. 2018;73(3):427–435. doi: 10.1016/j.eururo.2017.06.021..
DOI: 10.1016/j.eururo.2017.06.021
Leisser A., Nejabat M., Hartenbach M., Agha Mohammadi Sareshgi R., Shariat S., Kramer G. et al. Analysis of hematological parameters as prognostic markers for toxicity and survival of (223) Radium treatment. Oncotarget. 2018;9(22):16197–16204. doi: 10.18632/oncotarget.24610..
DOI: 10.18632/oncotarget.24610
McKay R.R., Jacobus S., Fiorillo M., Ledet E.M., Cotogna P.M., Steinberger A.E. et al. Radium-223 use in clinical practice and variables associated with completion of therapy. Clin Genitourin Cancer. 2017;15:e289–98. doi: 10.1016/j.clgc.2016.08.015..
DOI: 10.1016/j.clgc.2016.08.015
Morris M.J., Hammers H.J., Sweeney C., Antonarakis E.S., Cho S.Y., PanditTaskar N. et al. Safety of radium-223 dichloride (Ra-223) with docetaxel (D) in patients with bone metastases from castration-resistant prostate cancer (CRPC): A phase I Prostate Cancer Clinical Trials Consortium Study. J Clin Oncol. 2013;31(15S):5021. doi: 10.1200/jco.2013.31.15_suppl.5021..
DOI: 10.1200/jco.2013.31.15_suppl.5021
Dan T.D., Eldredge-Hindy H.B., Hoffman-Censits J., Lin J., Kelly W.K., Gomella L.G. et al. Hematologic toxicity of concurrent administration of Radium-223 and next-generation antiandrogen therapies. Am J Clin Oncol. 2017;40(4):342–347. doi: 10.1097/COC.0000000000000181..
DOI: 10.1097/COC.0000000000000181
Van den Wyngaert T., Tombal B. The changing role of radium-223 in metastatic castrate-resistant prostate cancer: has the EMA missed the mark with revising the label? Q J Nucl Med Mol Imaging. 2019;63(2):170–182. doi: 10.23736/S1824-4785.19.03205-9..
DOI: 10.23736/S1824-4785.19.03205-9
Stolten M.D.D., Steinberger A.E.E., Cotogno P.M.M., Ledet E.M.M., Lewis B.E.E., Sartor O. Parameters associated with 6 cycles of radium-223 dichloride therapy in metastatic castrate-resistant prostate cancer. Int J Radiat Oncol Biol Phys. 2015:93(3):E196. doi: 10.1016/j.ijrobp.2015.07.1047..
DOI: 10.1016/j.ijrobp.2015.07.1047
Parikh S., Murray L., Kenning L., Bottomley D., Din O., Dixit S. et al. Realworld outcomes and factors predicting survival and completion of radium 223 in metastatic castrate-resistant prostate cancer. Clin Oncol (R Coll Radiol). 2018;30(9):548–555. doi: 10.1016/j.clon.2018.06.004..
DOI: 10.1016/j.clon.2018.06.004
van der Doelen M.J., Kuppen M.C.P., Jonker M.A., Mehra N., Janssen M.J.R., van Oort I.M., Gerritsen W.R. 223Ra therapy in patients with advanced castrationresistant prostate cancer with bone metastases: lessons from daily practice. Clin Nucl Med. 2018;43(1):9–16. doi: 10.1097/RLU.0000000000001904..
DOI: 10.1097/RLU.0000000000001904
Kuppen M.C.P., Westgeest H.M., van der Doelen M.J., van den Eertwegh A.J.M., Coenen J.L.L.M., Aben K.K.H. et al. Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer. Fut Oncol. 2020;16(19):1371–1384. doi: 10.2217/fon-2020-0039..
DOI: 10.2217/fon-2020-0039
Dondossola E., Casarin S., Paindelli C., De-Juan-Pardo E.M., Hutmacher D.W., Logothetis C.J., Friedl P. Radium 223-Mediated Zonal Cytotoxicity of Prostate Cancer in Bone. J Nat Cancer Instit. 2019;111(10):1042–1050. doi: 10.1093/jnci/djz007..
DOI: 10.1093/jnci/djz007
Casarin S., Dondossola E. An agent-based model of prostate Cancer bone metastasis progression and response to Radium223. BMC Cancer. 2020;20:605–624. doi: 10.1186/s12885-020-07084-w..
DOI: 10.1186/s12885-020-07084-w
Mota J.M., Armstrong A.J., Larson S.M., Fox J.J., Morris M.J. Measuring the unmeasurable: automated bone scan index as a quantitative endpoint in prostate cancer clinical trials. Prostate Cancer Prostatic Dis. 2019;22(4):522–530. doi: 10.1038/s41391-019-0151-4..
DOI: 10.1038/s41391-019-0151-4
Song H., Jin S., Xiang P., Hu S., Jin J. Prognostic value of the bone scan index in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. BMC Cancer. 2020;20(1):238. doi: 10.1186/s12885-020-06739-y..
DOI: 10.1186/s12885-020-06739-y
Graff J.N., Beer T.M. Pharmacotherapeutic management of metastatic, castration-resistant prostate cancer in the elderly: focus on non-chemotherapyagents. Drugs Aging. 2014;31(12):873–882. doi: 10.1007/s40266-014-0224-y..
DOI: 10.1007/s40266-014-0224-y
Poeppel T.D., Handkiewicz-Junak D., Andreeff M., Becherer A., Bockisch A., Fricke E. et al. EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45(5):824–845. doi: 10.1007/s00259-017-3900-4..
DOI: 10.1007/s00259-017-3900-4
Sartor A.O., Heinrich D., Mariados N., Méndez-Vidal M.J., Keizman D., Thellen- berg-Karlsson C. et al. Radium-223 (Ra-223) re-treatment (Re-tx): First experience from an international, multicenter, prospective study in patients (Pts) with castration-resistant prostate cancer and bone metastases (mCRPC).J Clin Oncol. 2016;34(2S):197. doi: 10.1200/jco.2016.34.2_suppl.197..
DOI: 10.1200/jco.2016.34.2_suppl.197
Fizazi K., Massard C., Smith M., Rader M., Brown J., Milecki P. et al. Bonerelated parameters are the main prognostic factors for overall survival in men with bone metastases from castration-resistant prostate cancer. Eur Urol. 2015;68(1):42–50. doi: 10.1016/j.eururo.2014.10.001..
DOI: 10.1016/j.eururo.2014.10.001
Sartor A.O., Amariglio R., Wilhelm S., Garcia-Vargas J., O’Bryan-Tear C.G., Shan M. et al. Correlation between baseline variables and survival in the radium-223 dichloride (Ra-223) phase III ALSYMPCA trial with attention to total ALP changes. J Clin Oncol. 2013;31(15S):5080. doi: 10.1200/jco.2013.31.15_suppl.5080..
DOI: 10.1200/jco.2013.31.15_suppl.5080
Sartor A.O., Amariglio R., Wilhelm S., Garcia-Vargas J., O’Bryan-Tear C.G., Shan M. et al. Correlation between baseline variables and survival in the radium-223 dichloride (Ra-223) phase III ALSYMPCA trial with attention to total ALP changes. J Clin Oncol. 2013;31(15S):5080. doi: 10.1200/jco.2013.31.15_suppl.5080..
DOI: 10.1200/ jco.2013.31.15_suppl.5080
Nilsson S., Franzen L., Parker C., Tyrrell C., Blom R., Tennval J. et al. Bonetargeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol. 2007;8(7):587–594. doi: 10.1016/S1470-2045(07)70147-X..
DOI: 10.1016/S1470-2045(07)70147-X
Nome R., Hernes E., Bogsrud T.V., Bjoro T., Fossa S.D. Changes in prostate-specific antigen, markers of bone metabolism and bone scans after treatment with radium-223. Scand J Urol. 2015;49(3):211–217. doi: 10.3109/21681805.2014.982169..
DOI: 10.3109/21681805.2014.982169
Etchebehere E.C., Milton D.R., Araujo J.C., Swanston N.M., Macapinlac H.A., Rohren E.M. Factors affecting (223)Ra therapy: clinical experience after 532 cycles from a single institution. Eur J Nucl Med Mol Imaging. 2016;43(1):8–20. doi: 10.1007/s00259-015-3185-4..
DOI: 10.1007/s00259-015-3185-4
Kelloff G.J., Coffey D.S., Chabner B.A., Dicker A.P., Guyton K.Z., Nisen P.D. et al. Prostate-specific antigen doubling time as a surrogate marker for evaluation of oncologic drugs to treat prostate cancer. Clin Cancer Res. 2004;10(11):3927–3933. doi: 10.1158/1078-0432.CCR-03-0788..
DOI: 10.1158/1078-0432.CCR-03-0788
Parker C., Finkelstein S.E., Michalski J.M., O’Sullivan J.M., Bruland O., Vogelzang N.J. et al. Efficacy and safety of radium-223 dichloride in symptomatic castration-resistant prostate cancer patients with or without baseline opioiduse from the phase 3 ALSYMPCA trial. Eur Urol. 2016;70(5):875–883. doi: 10.1016/j.eururo.2016.06.002..
DOI: 10.1016/j.eururo.2016.06.002
Sartor A.O., Fernandez D.C., Morris M.J., Iagaru A., Brown A., Almeida F. et al. Radium-223 experience in pretreated patients: EAP setting. J Clin Oncol. 2015;33(15S):5063. doi: 10.1200/jco.2015.33.15_suppl.5063..
DOI: 10.1200/jco.2015.33.15_suppl.5063
Prelaj A., Rebuzzi S.E., Buzzacchino F., Pozzi C., Ferrara C., Frantellizzi V. et al. Radium-223 in patients with metastatic castration-resistant prostate cancer: efficacy and safety in clinical practice. Oncol Lett. 2019;17(2):1467–1476.doi: 10.3892/ol.2018.9785..
DOI: 10.3892/ol.2018.9785
De Vincentis G., Follacchio G.A., Frantellizzi V., Prelaj A., Farcomeni A., Giuli A. et al. 223Ra-dichloride therapy in an elderly bone metastatic castrationresistant prostate cancer patient: a case report presentation and comparison with existing literature. Aging Clin Exp Res. 2018;30:677–680. doi: 10.1007/s40520-017-0826-4..
DOI: 10.1007/s40520-017-0826-4
McNamara M.A., George D.J. Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report. BMC Cancer. 2015;15:371. doi: 10.1186/s12885- 015-1390-y..
DOI: 10.1186/s12885- 015-1390-y
McNamara M.A., George D.J. Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report. BMC Cancer. 2015;15:371. doi: 10.1186/s12885- 015-1390-y..
DOI: 10.1186/s12885-015-1390-y
De Vincentis G., Follacchio G.A., Frantellizzi V., Liberatore M., Monteleone F., Cortesi E. Prostate-specific antigen flare phenomenon during 223Ra-dichloride treatment for bone metastatic castration-resistant prostate cancer: a case report. Clin Genitourin Cancer. 2016;14(5):e529–e533. doi: 10.1016/j.clgc.2016.04.014..
DOI: 10.1016/j.clgc.2016.04.014
Castello A., Macapinlac H.A., Lopci E., Santos E.B. Prostate-specific antigen flare induced by 223RaCl2 in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45(13):2256–2263. doi: 10.1007/s00259-018-4051-y..
DOI: 10.1007/s00259-018-4051-y
Sartor O., Coleman R.E., Nilsson S., Heinrich D., Helle S.I., O’Sullivan J.M. et al. An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223. Ann Oncol. 2017;28(5):1090–1097. doi: 10.1093/annonc/ mdx044..
DOI: 10.1093/annonc/ mdx044
Sartor O., Coleman R.E., Nilsson S., Heinrich D., Helle S.I., O’Sullivan J.M. et al. An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223. Ann Oncol. 2017;28(5):1090–1097. doi: 10.1093/annonc/ mdx044..
DOI: 10.1093/annonc/mdx044
Rathbun J.T., Franklin G.E. Radium-223 (Xofigo) with concurrent abiraterone or enzalutamide: predictive biomarkers of improved overall survival in a clinically advanced cohort. Curr Probl Cancer. 2019;43(3):205–212. doi: 10.1016/j.currproblcancer.2018.05.007..
DOI: 10.1016/j.currproblcancer.2018.05.007
Sartor O., Vogelzang N.J., Sweeney C., Fernandez D.C., Almeida F., Iagaru A. et al. Radium-223 safety, efficacy, and concurrent use with abiraterone or enzalutamide: first U.S. experience from an expanded access program. Oncologist. 2018;23(2):193–202. doi: 10.1634/theoncologist.2017-0413..
DOI: 10.1634/theoncologist.2017-0413
Sciarra A., Gentilucci A., Salciccia S., Von Heland M., Ricciuti G.P., Marzio V. et al. Psychological and functional effect of different primary treatments for prostate cancer: a comparative prospective analysis. Urol Oncol. 2018;36(7):340.e7–e21. doi: 10.1016/j.urolonc.2018.03.022..
DOI: 10.1016/j.urolonc.2018.03.022
De Vincentis G., Monari F., Baldari S., Salgarello M., Frantellizzi V., Salvi E. et al. Narrative medicine in metastatic prostate cancer reveals ways to improve patient awareness & quality of care. Fut Oncol. 2018;14(27):2821–2832. doi: 10.2217/fon-2018-0318..
DOI: 10.2217/fon-2018-0318
Cursano M.C., Iuliani M., Casadei C., Stellato M., Tonini G., Paganelli G. et al. Combination radium-223 therapies in patients with bone metastases from castration-resistant prostate cancer: A review. Crit Rev Oncol Hematol. 2020;146:102864. doi: 10.1016/j.critrevonc.2020.102864..
DOI: 10.1016/j.critrevonc.2020.102864
Sartor O., Hoskin P., Coleman R.E., Nilsson S., Vogelzang N.J., Petrenciuc O. et al. Chemotherapy followingradium-223 dichloride treatment in ALSYMPCA. Prostate. 2016;76(10):905–916. doi: 10.1002/pros.23180..
DOI: 10.1002/pros.23180